Cargando…

Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia

BACKGROUND: Many studies have been published on the mutational status of patients with lung adenocarcinomas, and great population-based variability in mutation frequencies has been reported. The main objective of the present study was to analyze the EGFR, KRAS and ALK mutation status in a representa...

Descripción completa

Detalles Bibliográficos
Autores principales: Brcic, Luka, Jakopovic, Marko, Misic, Marija, Seiwerth, Fran, Kern, Izidor, Smojver-Jezek, Silvana, Quehenberger, Franz, Samarzija, Miroslav, Seiwerth, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031347/
https://www.ncbi.nlm.nih.gov/pubmed/27655296
http://dx.doi.org/10.1186/s13000-016-0544-9
_version_ 1782454793818603520
author Brcic, Luka
Jakopovic, Marko
Misic, Marija
Seiwerth, Fran
Kern, Izidor
Smojver-Jezek, Silvana
Quehenberger, Franz
Samarzija, Miroslav
Seiwerth, Sven
author_facet Brcic, Luka
Jakopovic, Marko
Misic, Marija
Seiwerth, Fran
Kern, Izidor
Smojver-Jezek, Silvana
Quehenberger, Franz
Samarzija, Miroslav
Seiwerth, Sven
author_sort Brcic, Luka
collection PubMed
description BACKGROUND: Many studies have been published on the mutational status of patients with lung adenocarcinomas, and great population-based variability in mutation frequencies has been reported. The main objective of the present study was to analyze the EGFR, KRAS and ALK mutation status in a representative cohort of patients in Croatia with lung adenocarcinomas and to correlate the mutational status with clinical data. METHODS: All patients who were newly diagnosed within 6 months with histologically proven primary lung adenocarcinomas were included. Mutational analyses for EGFR and KRAS mutations were performed in a cobas z 480 analyzer. ALK immunohistochemistry was performed using the D5F3 clone on Benchmark XT instrument. Clinical data were obtained from the medical records. RESULTS: Of the 324 patients, 59.9 % were male. At the time of diagnosis, the patients ranged in age range from 35 to 88 years (median 63 years). Most of the patients were current smokers or former smokers (77.2 %). EGFR mutations were found in 15.7 % of the patients, and of these mutations, exon 19 deletion was the most common (45.1 %). KRAS mutations were present in 34.9 % of the patients, while 4.1 % of patients were ALK-positive. The statistical significance of the presence of mutations was detected for both gender and smoking. CONCLUSION: The detected mutation rates demonstrated a slightly higher prevalence of KRAS mutations, but not a higher prevalence of EGFR mutations or ALK gene rearrangement, in comparison with the rates found in other European countries. EGFR and ALK mutational status showed a statistically significant correlation with gender as well as with smoking, while KRAS mutation status showed a statistically significant correlation only with smoking. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13000-016-0544-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5031347
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50313472016-09-29 Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia Brcic, Luka Jakopovic, Marko Misic, Marija Seiwerth, Fran Kern, Izidor Smojver-Jezek, Silvana Quehenberger, Franz Samarzija, Miroslav Seiwerth, Sven Diagn Pathol Research BACKGROUND: Many studies have been published on the mutational status of patients with lung adenocarcinomas, and great population-based variability in mutation frequencies has been reported. The main objective of the present study was to analyze the EGFR, KRAS and ALK mutation status in a representative cohort of patients in Croatia with lung adenocarcinomas and to correlate the mutational status with clinical data. METHODS: All patients who were newly diagnosed within 6 months with histologically proven primary lung adenocarcinomas were included. Mutational analyses for EGFR and KRAS mutations were performed in a cobas z 480 analyzer. ALK immunohistochemistry was performed using the D5F3 clone on Benchmark XT instrument. Clinical data were obtained from the medical records. RESULTS: Of the 324 patients, 59.9 % were male. At the time of diagnosis, the patients ranged in age range from 35 to 88 years (median 63 years). Most of the patients were current smokers or former smokers (77.2 %). EGFR mutations were found in 15.7 % of the patients, and of these mutations, exon 19 deletion was the most common (45.1 %). KRAS mutations were present in 34.9 % of the patients, while 4.1 % of patients were ALK-positive. The statistical significance of the presence of mutations was detected for both gender and smoking. CONCLUSION: The detected mutation rates demonstrated a slightly higher prevalence of KRAS mutations, but not a higher prevalence of EGFR mutations or ALK gene rearrangement, in comparison with the rates found in other European countries. EGFR and ALK mutational status showed a statistically significant correlation with gender as well as with smoking, while KRAS mutation status showed a statistically significant correlation only with smoking. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13000-016-0544-9) contains supplementary material, which is available to authorized users. BioMed Central 2016-09-21 /pmc/articles/PMC5031347/ /pubmed/27655296 http://dx.doi.org/10.1186/s13000-016-0544-9 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Brcic, Luka
Jakopovic, Marko
Misic, Marija
Seiwerth, Fran
Kern, Izidor
Smojver-Jezek, Silvana
Quehenberger, Franz
Samarzija, Miroslav
Seiwerth, Sven
Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
title Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
title_full Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
title_fullStr Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
title_full_unstemmed Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
title_short Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
title_sort analysis of the frequency of egfr, kras and alk mutations in patients with lung adenocarcinoma in croatia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5031347/
https://www.ncbi.nlm.nih.gov/pubmed/27655296
http://dx.doi.org/10.1186/s13000-016-0544-9
work_keys_str_mv AT brcicluka analysisofthefrequencyofegfrkrasandalkmutationsinpatientswithlungadenocarcinomaincroatia
AT jakopovicmarko analysisofthefrequencyofegfrkrasandalkmutationsinpatientswithlungadenocarcinomaincroatia
AT misicmarija analysisofthefrequencyofegfrkrasandalkmutationsinpatientswithlungadenocarcinomaincroatia
AT seiwerthfran analysisofthefrequencyofegfrkrasandalkmutationsinpatientswithlungadenocarcinomaincroatia
AT kernizidor analysisofthefrequencyofegfrkrasandalkmutationsinpatientswithlungadenocarcinomaincroatia
AT smojverjezeksilvana analysisofthefrequencyofegfrkrasandalkmutationsinpatientswithlungadenocarcinomaincroatia
AT quehenbergerfranz analysisofthefrequencyofegfrkrasandalkmutationsinpatientswithlungadenocarcinomaincroatia
AT samarzijamiroslav analysisofthefrequencyofegfrkrasandalkmutationsinpatientswithlungadenocarcinomaincroatia
AT seiwerthsven analysisofthefrequencyofegfrkrasandalkmutationsinpatientswithlungadenocarcinomaincroatia